{"protocolSection":{"identificationModule":{"nctId":"NCT03408262","orgStudyIdInfo":{"id":"Ad4HIV"},"organization":{"fullName":"Imperial College London","class":"OTHER"},"briefTitle":"Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women","officialTitle":"A Phase I Single-Blind Randomised Trial Investigating Immunisation Strategies Using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA Combinations in Order to Maximise Antibody Responses to Human Immunodeficiency Virus","acronym":"Ad4HIV"},"statusModule":{"statusVerifiedDate":"2024-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-10-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-02-10","type":"ACTUAL"},"completionDateStruct":{"date":"2020-02-10","type":"ACTUAL"},"studyFirstSubmitDate":"2018-01-05","studyFirstSubmitQcDate":"2018-01-16","studyFirstPostDateStruct":{"date":"2018-01-23","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-07-25","resultsFirstSubmitQcDate":"2024-10-11","resultsFirstPostDateStruct":{"date":"2024-10-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-10-11","lastUpdatePostDateStruct":{"date":"2024-10-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Imperial College London","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"A Phase I Single-Blind randomised trial investigating immunisation strategies using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA combinations in order to maximise antibody responses to Human Immunodeficiency Virus","detailedDescription":"This is a randomised two-part Phase I study which will explore the impact of different boosting options (MVA-CN54 and recombinant CN54gp140 protein) for oral Adenovirus serotype 4 vector prime expressing HIV-1 CN54 envelope (Ad4-EnvCN54) designed to optimize systemic and mucosal antibody responses.\n\nPart 1 is exploratory and designed to select conditions capable of promoting enhanced systemic and mucosal B cell responses in a limited number of participants.\n\nPart 2 is dependent upon Part 1 and is designed to study groups selected on performance in part 1 in an expanded number of subjects. Data from both stages will be combined for safety and immunological analyses."},"conditionsModule":{"conditions":["Human Immunodeficiency Virus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":68,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group A","type":"ACTIVE_COMPARATOR","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo","interventionNames":["Biological: CN54gp140/MPLA"]},{"label":"Group B","type":"EXPERIMENTAL","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo","interventionNames":["Biological: Ad4-EnvCN54","Biological: CN54gp140/MPLA"]},{"label":"Group C","type":"EXPERIMENTAL","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo","interventionNames":["Biological: Ad4-EnvCN54","Biological: CN54gp140/MPLA"]},{"label":"Group D","type":"EXPERIMENTAL","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo","interventionNames":["Biological: Ad4-EnvCN54","Biological: CN54gp140/MPLA"]},{"label":"Group E","type":"ACTIVE_COMPARATOR","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54","interventionNames":["Biological: MVA-CN54","Biological: CN54gp140/MPLA"]},{"label":"Group F","type":"EXPERIMENTAL","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54","interventionNames":["Biological: Ad4-EnvCN54","Biological: MVA-CN54","Biological: CN54gp140/MPLA"]},{"label":"Group G","type":"EXPERIMENTAL","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54","interventionNames":["Biological: Ad4-EnvCN54","Biological: MVA-CN54","Biological: CN54gp140/MPLA"]},{"label":"Group H","type":"EXPERIMENTAL","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54","interventionNames":["Biological: Ad4-EnvCN54","Biological: MVA-CN54","Biological: CN54gp140/MPLA"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad4-EnvCN54","description":"Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54","armGroupLabels":["Group B","Group C","Group D","Group F","Group G","Group H"]},{"type":"BIOLOGICAL","name":"MVA-CN54","description":"Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54","armGroupLabels":["Group E","Group F","Group G","Group H"]},{"type":"BIOLOGICAL","name":"CN54gp140/MPLA","description":"Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","armGroupLabels":["Group A","Group B","Group C","Group D","Group E","Group F","Group G","Group H"],"otherNames":["CN54-M"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Mucosal Binding IgG Antibodies to HIV CN54gp140 Antigen","description":"Number of participants with mucosal (semen, nasal, vaginal or rectal) binding IgG antibodies to HIV CN54gp140 antigen, as determined by ELISA","timeFrame":"At two weeks after the final immunisation"},{"measure":"Number of Participants With Severe or Greater (Grades 3-4) Adverse Reactions During the Study","description":"Number of Participants With Severe or Greater (Grades 3-4) Adverse Reactions up to twenty-four weeks after the final immunisation","timeFrame":"Up to twenty-four weeks after the final immunisation"},{"measure":"Median Concentration of CN54-gp140 Specific IgG Binding Antibodies","description":"Median concentration of CN54-gp140 specific IgG binding antibodies, as measured by ELISA. Concentration is in ng/mL","timeFrame":"At two weeks after the final immunisation"}],"secondaryOutcomes":[{"measure":"Number of Participants With Detectable Serum Binding Antibodies to HIV CN54gp140 Antigen","description":"Number of participants with detectable serum binding antibodies to HIV CN54gp140 antigen, as measured by IgG binding ELISA","timeFrame":"At two weeks post-final immunisation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men and women aged between 18 and 50 years on the day of screening\n2. BMI between 18-30\n3. Seronegative for Adenovirus 4 serum neutralising antibodies\n4. Available for follow-up for the duration of the study\n5. Willing and able to give written informed consent\n6. At low risk of HIV infection and willing to remain so for the duration of the study defined as:\n\n   * no history of injecting drug use in the previous ten years\n   * no gonorrhoea or syphilis in the last six months\n   * no high risk partner (e.g. injecting drug use, HIV positive partner) either currently or within the past six months\n   * no unprotected anal or vaginal intercourse in the last six months, outside a relationship with a regular partner known to be HIV negative\n7. Willing to undergo HIV testing\n8. Willing to undergo a STI screen for chlamydia, gonorrhoea and syphilis\n9. Must agree to require male sexual partner to use condoms, from at least 14 days before the first vaccination until at least 4 months after the last\n10. If heterosexually active female capable of becoming pregnant, must (in addition to requiring male partner to use condoms) agree to use hormonal contraception, or to complete abstinence, from at least 30 days before the first vaccination until at least 4 months after the last. \\[Note: Acceptable hormonal contraception is combined (estrogen and progestogen containing) or progestogen-only hormonal contraception associated with inhibition of ovulation. Complete abstinence can be used, when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, lactational amenorrhoea method, and IUD/IUS are not acceptable methods of contraception.\\]\n11. If sexually active male, must agree to use condoms from the day of first vaccination until at least 4 months after the last. \\[Note: Additional use of an effective method of contraception is recommended for any non-pregnant female partner over the same period.\\]\n12. Agree to abstain from donating blood, eggs or sperm from the day of first vaccination until at least 3 months after the end of their participation in the trial\n13. Registered with a GP for at least the past month\n14. Entered and clearance obtained from The Overvolunteering Prevention System (TOPS) database\n\nExclusion Criteria:\n\n1. Are pregnant or breast feeding, or living with anyone under the age of 5 years old or over 75 years old\n2. Have close contact with an immunocompromised individual thought to be at clinical risk from Adenovirus infection\n3. Clinically relevant abnormality on history or examination including:\n\n   1. Liver disease with inadequate hepatic function\n   2. Any skin condition which may interfere with the trial assessment of the injection sites\n   3. Haematological, metabolic, gastrointestinal or cardio-pulmonary disorders\n   4. Uncontrolled infection; autoimmune disease, immunodeficiency\n4. Known hypersensitivity to any component of the vaccine formulations used in this trial, or have severe or multiple allergies to drugs or pharmaceutical agents\n5. History of severe local or general reaction to vaccination defined as\n\n   * Local: extensive, indurated redness and swelling involving most of the antero-lateral thigh or the arm, not resolving within 72 hours\n   * General: fever ≥39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours\n6. Receipt of live attenuated vaccine within 60 days or other vaccine within 30 days of enrolment\n7. Receipt of an experimental vaccines containing HIV antigens, Ad4 and MVA-C products at any time in the past\n8. Receipt of blood products or immunoglobin within 4 months of screening, or drugs that suppress the immune system, such as steroids (including inhaled steroids, excluding topical steroids unless applied to the upper arm), in the preceding 3 months\n9. Participating in another trial of a medicinal product, completed less than 30 days prior to enrolment\n10. HIV 1 or 2 positive or indeterminate on screening\n11. Positive for antibodies to hepatitis B surface antigen, hepatitis C antibody or serology indicating active syphilis requiring treatment\n12. Clinically significant positive reaction in antinuclear antibody screen or clinically significant immunoglobulin (IgA, IgG or IgM) values\n13. Grade 1 or above clinically significant routine laboratory parameters\n14. Unable to read and/or speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent\n15. Women with a history of toxic shock syndrome\n16. Women using an intrauterine device for contraception (as incompatible with softcup sampling)\n17. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data\n18. Unlikely to comply with protocol","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"David Lewis, MD","affiliation":"Imperial College London","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"NIHR Imperial Clinical Research Facility","city":"London","zip":"W12 0HS","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Group A","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"FG001","title":"Group B","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"FG002","title":"Group C","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"FG003","title":"Group D","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"FG004","title":"Group E","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"FG005","title":"Group F","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"FG006","title":"Group G","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"FG007","title":"Group H","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"9"},{"groupId":"FG007","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Healthy male or female adults, 18 to 50 years of age, at low risk for HIV infection.","groups":[{"id":"BG000","title":"Group A","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"BG001","title":"Group B","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"BG002","title":"Group C","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"BG003","title":"Group D","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"BG004","title":"Group E","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"BG005","title":"Group F","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"BG006","title":"Group G","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"BG007","title":"Group H","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"BG008","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"68"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"68"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"29"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"39"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White British","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"28"}]}]},{"title":"White Irish","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]},{"title":"Any other white background","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"17"}]}]},{"title":"Indian","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"4"}]}]},{"title":"Pakistani","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]},{"title":"Bangladeshi","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]},{"title":"Any other Asian background","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"6"}]}]},{"title":"Mixed White and Black Caribbean","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]},{"title":"Mixed White and Black African","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]},{"title":"Mixed White and Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]},{"title":"Any other Mixed background","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"2"}]}]},{"title":"Black Caribbean","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"3"}]}]},{"title":"Black African","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"4"}]}]},{"title":"Any other Black background","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"68"}]}]}]},{"title":"Number of participants with CN54-gp140 IgG antibodies at time of vaccination","description":"CN54-gp140 serum IgG antibodies were measured at baseline, before the participants received any vaccinations","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Mucosal Binding IgG Antibodies to HIV CN54gp140 Antigen","description":"Number of participants with mucosal (semen, nasal, vaginal or rectal) binding IgG antibodies to HIV CN54gp140 antigen, as determined by ELISA","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At two weeks after the final immunisation","groups":[{"id":"OG000","title":"Group A","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG001","title":"Group B","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG002","title":"Group C","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG003","title":"Group D","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG004","title":"Group E","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG005","title":"Group F","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG006","title":"Group G","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG007","title":"Group H","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Severe or Greater (Grades 3-4) Adverse Reactions During the Study","description":"Number of Participants With Severe or Greater (Grades 3-4) Adverse Reactions up to twenty-four weeks after the final immunisation","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to twenty-four weeks after the final immunisation","groups":[{"id":"OG000","title":"Group A","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG001","title":"Group B","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG002","title":"Group C","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG003","title":"Group D","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG004","title":"Group E","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG005","title":"Group F","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG006","title":"Group G","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG007","title":"Group H","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"}]}]}]},{"type":"PRIMARY","title":"Median Concentration of CN54-gp140 Specific IgG Binding Antibodies","description":"Median concentration of CN54-gp140 specific IgG binding antibodies, as measured by ELISA. Concentration is in ng/mL","populationDescription":"Serum from participants at two weeks after the final immunisation","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"ng/mL","timeFrame":"At two weeks after the final immunisation","groups":[{"id":"OG000","title":"Group A","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG001","title":"Group B","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG002","title":"Group C","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG003","title":"Group D","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG004","title":"Group E","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG005","title":"Group F","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG006","title":"Group G","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG007","title":"Group H","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"464","lowerLimit":"23","upperLimit":"1521"},{"groupId":"OG001","value":"14141","lowerLimit":"3971","upperLimit":"18348"},{"groupId":"OG002","value":"8992","lowerLimit":"3798","upperLimit":"79435"},{"groupId":"OG003","value":"11367","lowerLimit":"398","upperLimit":"26149"},{"groupId":"OG004","value":"6280","lowerLimit":"1102","upperLimit":"15044"},{"groupId":"OG005","value":"9639","lowerLimit":"3250","upperLimit":"14282"},{"groupId":"OG006","value":"20512","lowerLimit":"10583","upperLimit":"36552"},{"groupId":"OG007","value":"9041","lowerLimit":"4735","upperLimit":"21023"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Detectable Serum Binding Antibodies to HIV CN54gp140 Antigen","description":"Number of participants with detectable serum binding antibodies to HIV CN54gp140 antigen, as measured by IgG binding ELISA","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At two weeks post-final immunisation","groups":[{"id":"OG000","title":"Group A","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG001","title":"Group B","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG002","title":"Group C","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG003","title":"Group D","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG004","title":"Group E","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG005","title":"Group F","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG006","title":"Group G","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"},{"id":"OG007","title":"Group H","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"12 months","description":"All adverse events were recorded. Grades were defined as 1 (mild), 2 (moderate), 3 (severe) or 4 (life threatening).","eventGroups":[{"id":"EG000","title":"Group A","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":6,"otherNumAtRisk":12},{"id":"EG001","title":"Group B","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":3,"otherNumAtRisk":6},{"id":"EG002","title":"Group C","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":1,"seriousNumAtRisk":6,"otherNumAffected":2,"otherNumAtRisk":6},{"id":"EG003","title":"Group D","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":9,"otherNumAtRisk":12},{"id":"EG004","title":"Group E","description":"Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":3,"otherNumAtRisk":6},{"id":"EG005","title":"Group F","description":"Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":1,"seriousNumAtRisk":6,"otherNumAffected":3,"otherNumAtRisk":6},{"id":"EG006","title":"Group G","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":3,"otherNumAtRisk":6},{"id":"EG007","title":"Group H","description":"Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54\n\nAd4-EnvCN54: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nMVA-CN54: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54\n\nCN54gp140/MPLA: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":3,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6}],"seriousEvents":[{"term":"Depressive Disorder Triggering Overdose","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"UTI on Kidney stones","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Blood loss anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Haematemesis secondary to Mallory Weiss","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Concussion","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Cellulitis on hand","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Diverticulitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]}],"otherEvents":[{"term":"Myalgia","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Tenderness left arm","organSystem":"Product Issues","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Anal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":7,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Fungal skin infection","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":3,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dizziness","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Headache","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":3,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Right wrist synovialcyst surgical removal","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Rhinorrhoea/nasopharyngitis/rhinitis/cold/upper respiratory tract infection","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":6},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG006","numEvents":4,"numAffected":3,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Road traffic accident","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Chromaturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":6}]},{"term":"Dysmenorrhea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Sports injury","organSystem":"Social circumstances","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Influenza like illness","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Lateral femoral nerve compression","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Vomiting, vision blurred, headache and fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hangover/Alcoholic Withdrawal Symptoms","organSystem":"Social circumstances","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Thrombocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Gastroenteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Mouth Ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Toothache","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Feverish","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Eye pruritis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dygeusia","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Urinary tract infection","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Testicular pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Oropharyngeal discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Biceps tendon tenderness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Pruritis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Cystitis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"shoulder/clavicle region tenderness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Vulvovaginal pruritus","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Threadworm infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (19.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":6}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Research Integrity Officer","organization":"Imperial College London","email":"rgit@imperial.ac.uk","phone":"020 7594 1872"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-11-01","uploadDate":"2022-07-25T10:32","filename":"Prot_000.pdf","size":614431},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-07-20","uploadDate":"2022-07-25T10:35","filename":"SAP_001.pdf","size":302775}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D000163","term":"Acquired Immunodeficiency Syndrome"}],"ancestors":[{"id":"D015658","term":"HIV Infections"},{"id":"D000086982","term":"Blood-Borne Infections"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D015229","term":"Sexually Transmitted Diseases, Viral"},{"id":"D012749","term":"Sexually Transmitted Diseases"},{"id":"D016180","term":"Lentivirus Infections"},{"id":"D012192","term":"Retroviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012897","term":"Slow Virus Diseases"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D007153","term":"Immunologic Deficiency Syndromes"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":true}